BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35062992)

  • 1. Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors.
    Xiao F; Zhang L; Yang S; Peng K; Hua T; Tang G
    J Ovarian Res; 2022 Jan; 15(1):13. PubMed ID: 35062992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced T
    Han X; Sun M; Wang M; Fan R; Chen D; Xie L; Liu A
    Eur J Radiol; 2019 Sep; 118():187-193. PubMed ID: 31439240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI features and score for differentiating borderline from malignant epithelial ovarian tumors.
    Li YA; Qiang JW; Ma FH; Li HM; Zhao SH
    Eur J Radiol; 2018 Jan; 98():136-142. PubMed ID: 29279152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of normalized apparent diffusion coefficients in differentiating between borderline and malignant epithelial ovarian tumors.
    Lu J; Pi S; Ma FH; Zhao SH; Li HM; Cai SL; Qiang JW
    Eur J Radiol; 2019 Sep; 118():44-50. PubMed ID: 31439257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion kurtosis imaging for differentiating borderline from malignant epithelial ovarian tumors: A correlation with Ki-67 expression.
    Li HM; Zhao SH; Qiang JW; Zhang GF; Feng F; Ma FH; Li YA; Gu WY
    J Magn Reson Imaging; 2017 Nov; 46(5):1499-1506. PubMed ID: 28295854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors.
    Huang K; Xu S; Wang J; Ge L; Xu J; Jia X
    J Ovarian Res; 2023 Feb; 16(1):37. PubMed ID: 36759870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histogram Analysis Comparison of Monoexponential, Advanced Diffusion-Weighted Imaging, and Dynamic Contrast-Enhanced MRI for Differentiating Borderline From Malignant Epithelial Ovarian Tumors.
    He M; Song Y; Li H; Lu J; Li Y; Duan S; Qiang J
    J Magn Reson Imaging; 2020 Jul; 52(1):257-268. PubMed ID: 31922327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of contrast-enhanced dual-energy spectral CT for differentiating borderline from malignant epithelial ovarian tumours.
    Han X; Li B; Sun M; Li J; Li Y; Liu A
    Clin Radiol; 2021 Aug; 76(8):585-592. PubMed ID: 34059294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation.
    Zhao SH; Qiang JW; Zhang GF; Ma FH; Cai SQ; Li HM; Wang L
    Eur Radiol; 2014 Sep; 24(9):2292-9. PubMed ID: 24871335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Texture Analysis of Three-Dimensional MRI Images May Differentiate Borderline and Malignant Epithelial Ovarian Tumors.
    Ye R; Weng S; Li Y; Yan C; Chen J; Zhu Y; Wen L
    Korean J Radiol; 2021 Jan; 22(1):106-117. PubMed ID: 32932563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI for differentiation of borderline ovarian tumors from stage I malignant epithelial ovarian tumors using multivariate logistic regression analysis.
    Denewar FA; Takeuchi M; Urano M; Kamishima Y; Kawai T; Takahashi N; Takeuchi M; Kobayashi S; Honda J; Shibamoto Y
    Eur J Radiol; 2017 Jun; 91():116-123. PubMed ID: 28629557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.
    Shin JE; Choi HJ; Kim MH; Cho KS
    Korean J Radiol; 2011; 12(4):456-62. PubMed ID: 21852906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
    Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
    Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
    Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.